Libmeldy

Atidarsagene autotemcel, the active ingredient in Libmeldy, is a gene therapy (ex vivo autologous hematopoietic stem cell transduction) presented as an autologous CD34+ hematopoietic stem cell suspension for intravenous use. It is indicated for the treatment of metachromatic leukodystrophy in eligible patients.

GNH USA supplies Libmeldy as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, transplant centres and clinics worldwide.

Libmeldy is a gene‑therapy product indicated for metachromatic leukodystrophy, a lysosomal storage disorder affecting the central nervous system. - Late‑infantile metachromatic leukodystrophy: aims to halt disease progression and preserve motor and cognitive function when administered early. - Juvenile metachromatic leukodystrophy: seeks to stabilize neurological decline and improve quality of life in eligible patients. - Adult metachromatic leukodystrophy: intended to reduce further neurological deterioration and support functional abilities.

Libmeldy may be associated with a range of adverse reactions following infusion of genetically modified stem cells.

Common Side Effects: - Infusion‑related reactions such as fever, chills, and nausea. - Transient fatigue or headache. - Cytopenias including anemia and thrombocytopenia. - Mild gastrointestinal upset. - Transient elevation of liver enzymes. - Local site discomfort at infusion site.

Serious or Rare Side Effects: - Insertional oncogenesis leading to malignancy. - Graft failure or poor stem‑cell engraftment. - Severe infections due to immunosuppression. - Organ toxicity, including hepatic or renal impairment. - Neurological complications such as seizures. - Immune‑mediated reactions including cytokine release syndrome.

Libmeldy requires careful patient selection and monitoring throughout treatment. - Patient selection: confirm definitive diagnosis of metachromatic leukodystrophy and appropriate disease stage. - Pre‑infusion conditioning: administer recommended myeloablative or reduced‑intensity chemotherapy as per protocol. - Monitoring: observe for infusion reactions, hematologic parameters, and organ function during and after administration. - Infection risk: implement prophylactic antimicrobial measures and avoid live vaccines during immunosuppression. - Long‑term follow‑up: assess for insertional mutagenesis and secondary malignancies. - Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Libmeldy may interact with other therapies that affect hematopoiesis or immune function.

Major Interactions (Avoid): - Myelosuppressive chemotherapy agents: may exacerbate cytopenias. - Live vaccines: increased risk of severe infection. - Potent immunosuppressants: could impair stem‑cell engraftment.

Moderate Interactions (Monitor Closely): - Anticoagulants: monitor for bleeding complications. - Other gene‑therapy products: avoid overlapping vector exposure. - CYP enzyme modulators: generally minimal effect but monitor clinical response.